Newron Pharmaceuticals Highlights Evenamide at ECNP Congress 2025

Newron Pharmaceuticals S.p.A. is set to unveil new analyses and updates on evenamide as an add-on treatment for schizophrenia during the 38th ECNP Congress held in Amsterdam from October 11 to 14, 2025. The company will present three posters focused on its Phase III program, with a particular emphasis on treatment-resistant schizophrenia (TRS).

Findings from previous phases II and III studies have shown that evenamide benefits patients with TRS by improving both positive and negative symptoms. Notably, evenamide was well tolerated without typical antipsychotic side effects.

Additional post-hoc analyses reinforced the long-lasting effectiveness of evenamide, with more than 25% of patients achieving remission over one year. Furthermore, these results have initiated the ENIGMA-TRS 1 study, a pivotal Phase III trial designed to assess evenamide's efficacy as an add-on to second-generation antipsychotic medications in TRS patients.